312 related articles for article (PubMed ID: 22781742)
1. Medication discovery for addiction: translating the dopamine D3 receptor hypothesis.
Newman AH; Blaylock BL; Nader MA; Bergman J; Sibley DR; Skolnick P
Biochem Pharmacol; 2012 Oct; 84(7):882-90. PubMed ID: 22781742
[TBL] [Abstract][Full Text] [Related]
2. Current Perspectives on Selective Dopamine D
Newman AH; Xi ZX; Heidbreder C
Curr Top Behav Neurosci; 2023; 60():157-201. PubMed ID: 35543868
[TBL] [Abstract][Full Text] [Related]
3. Reduction of cocaine self-administration and D3 receptor-mediated behavior by two novel dopamine D3 receptor-selective partial agonists, OS-3-106 and WW-III-55.
Cheung TH; Loriaux AL; Weber SM; Chandler KN; Lenz JD; Schaan RF; Mach RH; Luedtke RR; Neisewander JL
J Pharmacol Exp Ther; 2013 Nov; 347(2):410-23. PubMed ID: 24018640
[TBL] [Abstract][Full Text] [Related]
4. Characterization of the transport, metabolism, and pharmacokinetics of the dopamine D3 receptor-selective fluorenyl- and 2-pyridylphenyl amides developed for treatment of psychostimulant abuse.
Mason CW; Hassan HE; Kim KP; Cao J; Eddington ND; Newman AH; Voulalas PJ
J Pharmacol Exp Ther; 2010 Jun; 333(3):854-64. PubMed ID: 20228156
[TBL] [Abstract][Full Text] [Related]
5. Current drug treatments targeting dopamine D3 receptor.
Leggio GM; Bucolo C; Platania CB; Salomone S; Drago F
Pharmacol Ther; 2016 Sep; 165():164-77. PubMed ID: 27343365
[TBL] [Abstract][Full Text] [Related]
6. Targeting the dopamine D3 receptor: an overview of drug design strategies.
Cortés A; Moreno E; Rodríguez-Ruiz M; Canela EI; Casadó V
Expert Opin Drug Discov; 2016 Jul; 11(7):641-64. PubMed ID: 27135354
[TBL] [Abstract][Full Text] [Related]
7. Identifying Medication Targets for Psychostimulant Addiction: Unraveling the Dopamine D3 Receptor Hypothesis.
Keck TM; John WS; Czoty PW; Nader MA; Newman AH
J Med Chem; 2015 Jul; 58(14):5361-80. PubMed ID: 25826710
[TBL] [Abstract][Full Text] [Related]
8. High Affinity Dopamine D3 Receptor (D3R)-Selective Antagonists Attenuate Heroin Self-Administration in Wild-Type but not D3R Knockout Mice.
Boateng CA; Bakare OM; Zhan J; Banala AK; Burzynski C; Pommier E; Keck TM; Donthamsetti P; Javitch JA; Rais R; Slusher BS; Xi ZX; Newman AH
J Med Chem; 2015 Aug; 58(15):6195-213. PubMed ID: 26203768
[TBL] [Abstract][Full Text] [Related]
9. Highly Selective Dopamine D3 Receptor (D3R) Antagonists and Partial Agonists Based on Eticlopride and the D3R Crystal Structure: New Leads for Opioid Dependence Treatment.
Kumar V; Bonifazi A; Ellenberger MP; Keck TM; Pommier E; Rais R; Slusher BS; Gardner E; You ZB; Xi ZX; Newman AH
J Med Chem; 2016 Aug; 59(16):7634-50. PubMed ID: 27508895
[TBL] [Abstract][Full Text] [Related]
10. Investigation of Novel Primary and Secondary Pharmacophores and 3-Substitution in the Linking Chain of a Series of Highly Selective and Bitopic Dopamine D
Shaik AB; Kumar V; Bonifazi A; Guerrero AM; Cemaj SL; Gadiano A; Lam J; Xi ZX; Rais R; Slusher BS; Newman AH
J Med Chem; 2019 Oct; 62(20):9061-9077. PubMed ID: 31526003
[TBL] [Abstract][Full Text] [Related]
11. Dopamine D3 Receptor Antagonist (GSK598809) Potentiates the Hypertensive Effects of Cocaine in Conscious, Freely-Moving Dogs.
Appel NM; Li SH; Holmes TH; Acri JB
J Pharmacol Exp Ther; 2015 Sep; 354(3):484-92. PubMed ID: 26177654
[TBL] [Abstract][Full Text] [Related]
12. Newly Developed Dopamine D
Jordan CJ; Humburg BA; Thorndike EB; Shaik AB; Xi ZX; Baumann MH; Newman AH; Schindler CW
J Pharmacol Exp Ther; 2019 Dec; 371(3):602-614. PubMed ID: 31562201
[TBL] [Abstract][Full Text] [Related]
13. Synthesis and pharmacological evaluation of potent and highly selective D3 receptor ligands: inhibition of cocaine-seeking behavior and the role of dopamine D3/D2 receptors.
Campiani G; Butini S; Trotta F; Fattorusso C; Catalanotti B; Aiello F; Gemma S; Nacci V; Novellino E; Stark JA; Cagnotto A; Fumagalli E; Carnovali F; Cervo L; Mennini T
J Med Chem; 2003 Aug; 46(18):3822-39. PubMed ID: 12930145
[TBL] [Abstract][Full Text] [Related]
14. Behavioral effects of cocaine and dopaminergic strategies for preclinical medication development.
Platt DM; Rowlett JK; Spealman RD
Psychopharmacology (Berl); 2002 Oct; 163(3-4):265-82. PubMed ID: 12373428
[TBL] [Abstract][Full Text] [Related]
15. Therapeutic doses of buspirone block D3 receptors in the living primate brain.
Kim SW; Fowler JS; Skolnick P; Muench L; Kang Y; Shea C; Logan J; Kim D; Carter P; King P; Alexoff D; Volkow ND
Int J Neuropsychopharmacol; 2014 Aug; 17(8):1257-67. PubMed ID: 24679922
[TBL] [Abstract][Full Text] [Related]
16. Selective antagonism at dopamine D3 receptors as a target for drug addiction pharmacotherapy: a review of preclinical evidence.
Heidbreder C
CNS Neurol Disord Drug Targets; 2008 Nov; 7(5):410-21. PubMed ID: 19128200
[TBL] [Abstract][Full Text] [Related]
17. A novel dopamine D3 receptor antagonist YQA14 inhibits methamphetamine self-administration and relapse to drug-seeking behaviour in rats.
Chen Y; Song R; Yang RF; Wu N; Li J
Eur J Pharmacol; 2014 Nov; 743():126-32. PubMed ID: 25261038
[TBL] [Abstract][Full Text] [Related]
18. Role of the dopamine D3 receptor in reactivity to cocaine-associated cues in mice.
Le Foll B; Francès H; Diaz J; Schwartz JC; Sokoloff P
Eur J Neurosci; 2002 Jun; 15(12):2016-26. PubMed ID: 12099907
[TBL] [Abstract][Full Text] [Related]
19. Effects of buspirone and the dopamine D3 receptor compound PG619 on cocaine and methamphetamine self-administration in rhesus monkeys using a food-drug choice paradigm.
John WS; Banala AK; Newman AH; Nader MA
Psychopharmacology (Berl); 2015 Apr; 232(7):1279-89. PubMed ID: 25327444
[TBL] [Abstract][Full Text] [Related]
20. Pharmacological actions of NGB 2904, a selective dopamine D3 receptor antagonist, in animal models of drug addiction.
Xi ZX; Gardner EL
CNS Drug Rev; 2007; 13(2):240-59. PubMed ID: 17627675
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
